This study describes the fabrication of a multifunctional nanosystem designed to combine chemotherapy with light-activated therapies for laryngeal cancer. Copper oxide nanoparticles (CO NPs) were functionalized with the photosensitizer chlorin e6 (C6) and coated with polydopamine (PD) to form a CO@C6-PD core. The chemotherapeutic agent docetaxel (DT) was then incorporated into this construct. Finally, folic acid (FA) was used as a targeting ligand to produce FA@CO@C6-PD/DT nanoparticles intended to preferentially target laryngeal cancer cells that overexpress folate receptors.
The rationale was to create a single nanoplatform capable of delivering cytotoxic chemotherapy while also enabling near-infrared (NIR) laser-triggered photothermal therapy (PTT) and photodynamic therapy (PDT), thereby achieving synergistic antitumor activity with lower invasiveness and potentially reduced systemic side effects.
According to the abstract, the FA@CO@C6-PD/DT particles exhibited a nanoscale diameter and an appropriate surface charge. The system demonstrated efficient docetaxel loading, colloidal stability, and a capacity for regulated DT release. The abstract does not provide specific numerical values for particle size, zeta potential, drug loading percentage, encapsulation efficiency, or release kinetics; those detailed metrics were not reported in the source abstract.
The authors report that the nanosystem showed cytocompatibility in the contexts tested and that docetaxel release could be controlled, consistent with its intended role as a drug delivery vehicle. The abstract does not specify which non-tumor cell types, if any, were used to assess cytocompatibility, nor does it provide quantitative release profiles or stability data over time in biological media.
In vitro antitumor efficacy was evaluated using TU212 laryngeal cancer cells. The FA@CO@C6-PD/DT nanoparticles produced significant synergistic antitumor effects when chemotherapy was combined with phototherapy. The abstract highlights a pronounced difference in potency with and without laser activation: the reported IC50 for FA@CO@C6-PD/DT under NIR laser exposure was 49 μg/mL, compared with 225 μg/mL without NIR exposure. This reduction in IC50 indicates enhanced cytotoxicity when the nanosystem was activated by NIR irradiation.
The abstract does not detail comparative controls (for example free docetaxel alone, CO@C6-PD without FA, or FA@CO@C6-PD without DT) beyond the comparison of laser versus no-laser conditions, nor does it state the duration of cell viability assays or replicate counts.
Photodynamic activation was performed using a 660 nm laser at an intensity of 2 W/cm2 for 6 minutes, as reported in the abstract. Under these conditions, FA@CO@C6-PD/DT generated elevated levels of reactive oxygen species (ROS). The increase in ROS production following light exposure is consistent with activation of the C6 photosensitizer and contributes to photodynamic-mediated tumor cell damage.
The abstract specifies the laser wavelength, power density, and irradiation time used in the reported experiments but does not provide quantitative ROS measurements, singlet oxygen yields, or comparative ROS levels versus controls.
Following laser-induced ROS generation, the authors observed alterations in mitochondrial membrane potential in TU212 cells treated with FA@CO@C6-PD/DT. These mitochondrial perturbations, together with combined chemotherapy and phototherapy effects, facilitated tumor cell death. While the abstract links ROS production and mitochondrial dysfunction to apoptosis and cell death, it does not present detailed apoptotic markers, caspase activation data, or flow cytometry results in the abstract text.
The authors conclude that FA@CO@C6-PD/DT represents a compelling nanoplatform for multimodal therapy in laryngeal cancer, enabling synergistic chemotherapy, PTT, and PDT with enhanced antitumor efficacy in TU212 cells. Key strengths highlighted include targeted delivery via folic acid, combined modality action, and improved potency under NIR activation (notably the decrease in IC50 from 225 to 49 μg/mL with laser exposure).
Limitations based on the abstract: the report focuses on in vitro findings in a single laryngeal cancer cell line (TU212). The abstract does not report in vivo efficacy, systemic toxicity, pharmacokinetics, long-term stability, or manufacturing considerations. Specific physicochemical and quantitative assay data (particle size distribution, zeta potential, loading efficiency, release kinetics, detailed ROS quantification, and apoptosis assays) are not provided in the abstract and therefore were not available for this summary.
Overall, the presented FA@CO@C6-PD/DT nanosystem is positioned as a promising candidate for further preclinical investigation to determine safety, biodistribution, and therapeutic efficacy in animal models prior to any consideration of clinical translation.